Crossmark

IBD risk prediction using multi-ethnic polygenic risk scores

Crossref DOI link: https://doi.org/10.1038/s41575-021-00425-5

Published Online: 2021-02-05

Published Print: 2021-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ananthakrishnan, Ashwin N. https://orcid.org/0000-0002-9436-1821
License Information

Text and Data Mining valid from 2021-02-05

Version of Record valid from 2021-02-05
More Information

Article History

Accepted: 29 January 2021

First Online: 5 February 2021

Competing interests

: A.N.A. has served on the scientific advisory board of Kyn Therapeutics, Sun Pharma and Gilead.